Purchase this article with an account.
V.D. Allen, E. Rechtman, L.M. Pratt, R.P. Danis; The Safety and Efficacy of Intravitreal Triamcinolone Acetonide Injections for the Treatment of Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4961.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the safety and efficacy of 4.0 mg intravitreal triamcinolone acetonide injections for treating choroidal neovascularization (CNV) in presumed ocular histoplasmosis syndrome(OHS) Methods: A retrospective analysis of all OHS subjects who were treated at Indiana University with iTAAC injections for new or recurrent CNV. The proportion of eyes that lost 15 or more and 30 or more ETDRS letters, mean logMAR visual acuity, lesion greatest linear dimension (GLD), and treatment side effects were assessed. Results: Fourteen patients with CNV due to OHS, aged 48.4± 17.3 years were evaluated. At baseline, 6 had subfoveal CNV, 7 had juxtafoveal CNV, and 1 had extrafoveal CNV. The mean follow-up was 11.6± 12.4 months, during which 11 subjects received one iTAAC injection and 3 received 3 iTAAC injections. Overall, 7% and 0% had lost 15 or more and 30 or more ETDRS letters, respectively. The mean logMAR visual acuity changed from 0.32±0.45 at baseline to 0.3±0.41 at the final visit. The mean lesion GLD decreased from 836±405µm at baseline to 814±432µm at the final visit. The side effects consisted of transient intraocular elevation in 57.1% of subjects and worsening of the cataract in 7 eyes. Conclusions: In a retrospective cohort study, iTAAC for CNV due to OHS, was found to be relatively safe and showed good visual outcome. Further studies are merited based on these results.
This PDF is available to Subscribers Only